Cuts FY25 adjusted EBITDA view to $395M-$405M from $470M-$480M. The company said, “As stated on the recent third quarter earnings call, the Company’s 2025 financial guidance did not include the impact of the initial payment under the licensing agreement. With the completion of the transaction, the Company has now updated its full year 2025 adjusted EBITDA guidance to reflect the initial $75 million cash payment.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target raised to $85 from $65 at Citi
- Cathie Wood Buys the Dip in Archer Aviation (ACHR) After Weak Q3 Results, Trims Stakes in Roku and TER Stocks
- Exact Sciences announces results from ALTUS study
- Exact Sciences Corp Faces Regulatory Risks Amid Potential Government Disruptions
- Exact Sciences Corp Reports Strong Q3 Earnings